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Introduction
Under the pretext of promoting "safe pregnancy termination services"l the
World Health Organization (WHO) is currently supporting a massive research
program for a vaccine which eliminates the human chorionic gonadotropin
(hCG) hormone in the maternal endocrine system. The demise of this placental
glycoprotein hormone annihilates the human blastocyst in its early life in the
mother's womb without "the maternal recognition of pregnancy."2,3 A major
premise behind this vaccine is that its users will not discover its full mode of
action. "Maternal recognition" would be a setback to its potential global market
given that the anti-hCG vaccine provokes antibodies resulting in an abortifacient
mechanism. 2,4 If this vaccine would eventually materialize, one may assume that
its marketing campaign would likely pay lip service to its users, promoting, as the
WHO's Fathalla would see it, "A reproductive rights and health approach, with
women at its center."l
Safety
It was with women at the "center" and at the expense of the "unwanted"
blastocyst that the WHO task Force on Birth Control Vaccines first attempted to
create a specific vaccine which would target hCG without interfering with other
related glycoprotein hormones such as thyrotropin, follitropin and lutropin.
Given that all these hormones share a common a-subunit, the task force focused
its attention on the B-subunit where the hCG includes a unique C-terminal
peptitude. The basic assumption was that a specific vaccine addressing the
carboxy-terminal portion of the hCG hormone (hCGBCTP) would eliminate the
possibility of cross-reaction with the human luteinizing hormone (hLH).4
However, all this came down in 1993 to the following statement:
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Although it is possible to generate specific monoclonal and polyclonal antibodies for
hCG by using hCGBCTP as an immunogen, it appear[s] that the biological response to
hCG [is] not affected by such antibodies. The reason for this is that the hCG-antibody
complex is still able to bind to target cell receptors and therefore the intended
contraceptive effect should not occur. In addition there is a risk of hazardous possible
side effects such as autoimmune reaction against the ovary because ... at least one
epitope is still accessible for antibody binding on receptor-bound hCG.s

As Roberge explained in an earlier issue of Lincare Quarterly, if such side
effects materialize, the vaccine user could experience premature menopause as
well as osteoporosis and cardiovascular problems.6
Thus, while the WHO hCG-specific hCGBCTP target antigen avoids the
immunological crossreactivity of hLHB and hCGB arising out of previous
hCG-based research, it lacks immunological efficacy and raises safety questions. 7
Such problems, along with Vaitukaitis et al.'s8 earlier writings, may shift the
research attention further away to the dimer oLHalhCGB; yet, the commonality
of certain a-epitopes present in the four hormones thyrotophin, chorionic
gonadotropin, lutropin and follitropin as well as the ovine luteinizing hormone
alpha, 9,10 along with studies about murine antibodies, 10, 11 ,12 result in another
warning from Dirnhofer, Wick and Berger about "the long-term safety of this
type of vaccine, since it might cause autoimmune reactions and endocrine
disturbances involving the gonads and the pituitary, such as secondary
hypothyroidism."7

Hurdles
Despite such recent scientific concern, promoters of anti-hCG vaccines may
seek to dispel the warnings by insisting that anti-hCG vaccines contain a
pregnancy-specific antigen which is both safe and reversible. Such a statement is
untenable under close scrutiny. Recent studies report a low hCG presence in
non-pregnant women,13,14 thus dispelling the myth endorsed by the WHO in
promoting its hCG research as a "pregnancy-specific" antigen. These studies also
raise as-yet-unanswered questions about the importance of low hCG levels in
non-pregnant women, which levels would be threatened by the vaccines.7 The
phase I clinical trials not only failed to address long-term safety concerns;2 they
also contained minimal information about individual cases despite the fact that
individual cases are of paramount importance for such types of vaccines.5
As to the reversibility issue, this can best be addressed as a long-term concern
best espoused by a parallel case concerning previous medical opinion that the
IUD was a reversible method. Yet, in 1995, a meta-analysis stud y l5 showed that
past IUD use could increase the risk of ectopic pregnancy. Events in the IUD
trade suggest that the safety hurdles for anti-hCG vaccines can be eventually
overcome through a similar variety of unethical tactics employed in the
marketing of IUDs. For example, over one-fourth of IUD insertions violate
medical guidelines, being inserted in patients with relative contraindications.16
Also there is evidence that some international IUD manufacturers withhold
critical information in their information guidelines. 17 In the United States,
30

Linacre Quarterly

women fitted with the ParaGard T380A IUD and the Progestasert IUD are asked
to sign lengthy contracts (11 pages each)18,19 which absolve the manufacturers from
a plethora of adverse reactions. If the WHO is to live up to its name, it should step in
and enforce proper accountability rather than let women suffer at their own expense
from widespread misconduct.
Conclusion

In Lei, Toth and Rao's study, the human fallopian tubes of non-pregnant women
immunostained for heG,14 further confirming Madersbacher et al.'s discovery of
heG in sera of healthy non-pregnant women. Thus, given that the anti-heG
vaccine is not a pregnancy-specific antigen as was originally claimed by the
sponsors and given the serious health questions surrounding its use, the World
Health Organization should re-examine its fixation with the vaccine. In the words
of Fathalla, "Demographic concerns of the past few decades, serious as they are,
should not override the human rights and health rationale of contraception." In
spite of such words of caution, it increasingly seems that the research about this
vaccine is being done with heG, and not "with women[,] at its center."
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